IPO roundup: Broncus Tech aims to breathe in $86M, Aegerion Pharma rides again, and more
Broncus Tech, medical device maker, files for $86M IPO — Broncus Technologies, a Mountain View, Calif., developer of minimally invasive devices for treating emphysema, filed to raise $86 million in an initial offering. The company’s SEC filing is here.
The Broncus technology is a minimally invasive,… Continue Reading
Life sciences briefing: Thursday, Nov. 15, 2007
Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma
EXPANDING ITEMS: Stay tuned.
Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart… Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech… Continue Reading
Life sciences briefing: Thursday, Aug. 16, 2007
Featured companies: Reliant Technologies, Leptos Biomedical, Calidora Skin Clinic
Reliant Tech seeks $95M IPO for dermatology lasers — Mountain View, Calif.-based Reliant Technologies, a developer of medical lasers for “skin rejuvenation” treatment, filed to raise as much as $95 million in an initial offering. The company currently… Continue Reading
Reliant Technologies raises $15M for aesthetic laser and surgery products
Reliant Technologies, a Mountain View, Calif. company that makes aesthetic laser medicine and surgery products, said it has raised $15 million in a fifth round of funding led by Delphi Ventures, Three Arch Partners and Meritech Capital Partners and others.
See statement here.